SuperX

About SuperX

SuperX Ltd. was a biopharmaceutical company that operated on a virtual model, a lean approach that emphasized outsourcing research and development to maintain a low overhead. The firm was established in 2016 and was strategically located at the Babraham Research Campus in Cambridge, United Kingdom, a hub for bioscience innovation. The company's primary focus was on developing novel anticoagulation therapeutics designed to prevent blood clots without the associated risk of bleeding, a significant challenge with existing treatments. Their core scientific endeavor was the discovery of antibodies targeting a specific, undisclosed component of the blood coagulation cascade.

The company was founded by a team with a notable record of success in the biotech space: David Grainger as CEO, Dr. Trevor Baglin as Chief Medical Officer, and Professor Jim Huntington as Chief Scientific Officer. This trio had previously founded XO1 Ltd., another virtual biotech with a similar focus on anticoagulants, which was successfully acquired by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, in 2015. This prior success was a key factor in attracting investors to SuperX. The founders' expertise is deeply rooted in the field; Dr. Baglin is a respected Consultant Haematologist with a history of identifying unique clinical insights, while Professor Huntington is a leading academic in Molecular Haemostasis at the University of Cambridge, specializing in the structural mechanisms of blood clotting. David Grainger, a partner at the venture capital firm Medicxi, brought his experience in founding and funding biotech ventures to the team.

SuperX's business strategy was centered on being a single-asset company, concentrating all its resources on its lead anticoagulant candidate. The company's approach to drug discovery was distinctive, drawing inspiration from observations of rare patient cases, or 'experiments of nature', to uncover new biological pathways that could be targeted for therapeutic intervention. This method aimed to sidestep the limitations of conventional scientific approaches. The company operated by collaborating with a network of contract research organizations (CROs), many of which were conveniently co-located at the Babraham campus, allowing it to compete with larger pharmaceutical companies at a fraction of the cost.

In February 2017, SuperX announced the completion of an $11 million Series A financing round. The investment was led by Medicxi and included participation from Johnson & Johnson Innovation – JJDC, Inc., the corporate venture arm of Johnson & Johnson. This funding was intended to advance their antibody discovery program with the goal of reaching clinical trials by 2019. Despite its promising start and the strong backing from its founders and investors, SuperX Ltd. eventually faced challenges and was reported to have entered bankruptcy and liquidation in April 2020.